Caren Mangarelli, a pediatrician who works with the Lurie Childrens Hospital's Pediatric Wellness & Weight Management Program, told ABC News that she believes the medications are only reaching a small percentage of teens who could potentially benefit from the drug, whether for type 2 diabetes and/or obesity, citing the statistic that nearly 20%, or around 14.7 million children and adolescents ages 2 to 19 in the U.S
This #PharmacyConnection article provides Designated Managers and pharmacy professionals with an overview of how they can continue to meet the requirements of the AIMS Program during the 2026 transition: To view or add a comment, sign in A significant inflection point in GLP-1s has just occurred
Research-peptide and compounded forms of afamelanotide are not FDA-approved for any indication.
Because of its delicate nature, it works well on a variety of skin types
Or does this just drive up healthcare spending with unclear long-term savings
How GLP-1 Drugs Are Transforming Consumer Behavior and What Businesses Should Do About It Contents This research was conducted on 12/17/25 and made possible using Virtual Audiences GLP-1 receptor agonists (medications like Ozempic, Wegovy, Mounjaro, and Zepbound) are no longer just treatments for diabetes or obesity
,aspect=ignore)
